Hormone receptor-positive (HR+) breast cancer represents the majority (69%) of breast cancer cases. While comparatively, HER2+ and triple negative breast cancer spaces have seen a number of practice changing advancements in the past few years, HR+ breast cancer has seen relatively few until recently. Within both early-stage and metastatic settings of HR+ breast cancer, new FDA approvals have stirred an evolving treatment approach.
Newly approved treatments have the potential to cause significant toxicity and require pharmacists to be aware of specific preventative measures and monitoring parameters. Clinical controversies appear throughout this treatment setting given the rapidly evolving nature, particularly when it comes to treatment sequencing. This clinical session will assist pharmacists caring for this patient population to be well-versed in treatment nuances.
This activity is approved for Board Certified Oncology Pharmacist (BCOP) recertification credit.
The BCOP Clinical Sessions are part of the professional development program for the recertification of board-certified oncology pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCOP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the BCOP Clinical Sessions posttests will be available on December 18, 2024, at www.accp.com/myaccount to anyone who has purchased access to the BCOP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 15, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 16, 2025.
Learning Objectives
1. Apply recent literature surrounding targeted therapy options in hormone receptor-positive (HR+), early-stage breast cancer.
2. Identify characteristics of early-stage HR+ breast cancer patients most likely to benefit from targeted adjuvant therapy.
3. Analyze literature regarding the integration of oral selective estrogen receptor degraders into current treatment guidelines.
4. Recommend appropriate treatment strategies for patients who qualify to receive inhibitors of the PI3K/AKT pathway.
5. Evaluate targeted treatment options beyond endocrine therapy for HR+ metastatic breast cancer.